Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ibuzatrelvir co-process API film coated tablet
Ibuzatrelvir co-process API film coated · 1 trial · 11 indications
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | single dose of ibuzatrelvir original tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment B | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment C | EXPERIMENTAL | single dose of ibuzatrelvir of the new tablet formulation dispersed in water and given in the fasted state on Day 1 of the treatment period |
| Treatment D | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fed state on Day 1 of the treatment period |
| Name | Type | Description |
|---|---|---|
| Ibuzatrelvir co-process API film coated tablet | DRUG | original |
| Ibuzatrelvir filmcoated tablet | DRUG | new |
Inclusion criteria: 1. 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs. 2. BMI of 16-32 kg/m2; and a tot...
Ibuzatrelvir co-process API film coated is an investigational small molecule antiviral tablet being developed by Pfizer, Inc. (PFE) for Coronavirus Disease 2019 (COVID-19). It is a film coated oral formulation of ibuzatrelvir, and it remains in clinical development rather than being an approved medicine.
It is being studied for the treatment of Coronavirus Disease 2019 (COVID-19), an infectious disease. The clinical program has also listed related respiratory tract infections and pneumonia among the conditions studied. It is investigational, so it is not yet an approved treatment for any indication.
Pfizer, Inc. is the developer of Ibuzatrelvir co-process API film coated. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company is responsible for the clinical development of this oral antiviral candidate for COVID-19.
Ibuzatrelvir co-process API film coated is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any use.
One Phase 1 trial of Ibuzatrelvir co-process API film coated has been completed: NCT07552779, titled A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir. It enrolled 17 healthy adult volunteers in Belgium and was a controlled, randomized study.
Yes. Ibuzatrelvir co-process API film coated tablet is another name for Ibuzatrelvir co-process API film coated. Both refer to the same Pfizer oral antiviral candidate being studied for Coronavirus Disease 2019 (COVID-19) in Phase 1 clinical development.